Previous close | 0.5000 |
Open | 0.4000 |
Bid | 0.3000 |
Ask | 0.6000 |
Strike | 50.00 |
Expiry date | 2025-01-17 |
Day's range | 0.4000 - 0.5000 |
Contract range | N/A |
Volume | |
Open interest | 4.3k |
Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). As components of the mCRM System, the devices are designed to work together wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therap
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.